Elevance Health Inc.

(New York Stock Exchange)
Back to all articles
Bullish +65

An $11 Billion Fund Is Betting Big on Elevance Health

Activist investor Earnings report Guidance raised AI-generated analysis

📈 ACR Alpine Capital Research increased its Elevance Health stake by 25% in Q3, bringing total holdings to 919,031 shares worth $357 million.

📊 Elevance raised its 2026 adjusted EPS guidance three times this year, most recently to a floor of at least $29.

💰 The company reported Q3 operating revenue growth of 0.7% to reach $50.4 billion despite rising operating expenses.

📉 Analyst consensus targets have climbed from $386 to $482, with the average target currently trading at a 15% premium.

🔮 Wall Street expects earnings to recover above 2023 levels by 2028, projecting EPS of $34.57 per share.

💹 Elevance stock trades at 15x forward earnings, which is slightly above its five-year average but below the April 2022 peak.

⚠️ The primary risk identified is that future growth projections depend on Elevance successfully hitting its self-set 12% EPS growth target for 2027.

📅 The upcoming Q4 earnings report in early next year will be critical for validating the company's continued guidance revisions.

Bullish Signals
  • ACR Alpine Capital Research added 25% to its Elevance Health stake, signaling strong institutional conviction in the company's current valuation and growth trajectory.
  • Elevance has raised its 2026 earnings guidance three times this year, demonstrating management's confidence in meeting or exceeding adjusted EPS targets.
  • The stock trades at a forward multiple of 15x earnings, which is close to the company's five-year average and suggests fair valuation relative to historical norms.
  • Analyst consensus price targets have increased significantly over the past year, with the average target now trading 15% above the current market price.
  • Elevance reported solid Q3 operating revenue growth of 0.7%, indicating continued business expansion despite macroeconomic headwinds.
Risk Factors
  • Adjusted operating expense ratios increased by 90 basis points in the third quarter, raising concerns about margin compression and cost control.
  • Future earnings growth projections are heavily dependent on Elevance successfully hitting its self-imposed 12% adjusted EPS growth target for 2027.
Full Analysis
ACR Alpine Capital Research has significantly increased its position in Elevance Health (ELV), adding 25% to its stake in the third quarter to reach 4.9% of its US equity holdings, valued at approximately $357 million. This strategic move positions Elevance as one of the fund's top ten largest positions, reflecting strong institutional confidence in the insurer's recent performance and forward-looking guidance. Elevance Health has demonstrated consistent upward revision to its earnings outlook throughout 2026, raising its adjusted EPS guidance three times this year to a minimum of $29. The company reported Q3 adjusted EPS of $6.99, driven by operating revenue growth of 0.7% to $50.4 billion, though costs have risen with an operating expense ratio increasing by 90 basis points. Wall Street analysts maintain a bullish consensus on Elevance, with average price targets currently 15% above the stock's recent trading price. Analysts project earnings growth returning to pre-2026 lows by 2028, reaching approximately $34.57 per share, while the stock trades at a forward multiple of 15x earnings, which is near its five-year historical average.